Biotech RadarJobs updated

COMPANY

PureTech Health

HQ: Boston, MA source · puretechhealth.com ↗ · New England

Clinical Phase 3

2 open jobs · last seen Oct 23, 2026 · 10 sources

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Idiopathic Pulmonary Fibrosis Drug Interactions Covid19 Post-acute COVID-19 Respiratory Disease Adult Recurrent AML Pharmacokinetic Analysis Pancreatic Cancer Urothelial Carcinoma Head and Neck Cancer Colorectal Cancer Breast Cancer Related Lymphoedema Lymphoedema LYT-200 LYT-100 LYT-300

2Open jobs9Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Director, Preclinical Research and DevelopmentBoston, MAOct 19, 2026Oct 20, 2026
PureTech does not accept agency resumes unless submitted through the portal on our ATS from a recruiting partner under contract for a particular assignment. PureTech will not be responsible for fees for resumes sent to employees or careers pages.PureTech HealthJan 22, 2020Oct 9, 2026

See all 2 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (2 open jobs at last check). source ↗
  2. Trial start Phase 3: Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) source ↗
  3. Trial start Phase 1: Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib source ↗
  4. Trial start 1: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) source ↗
  5. Trial start Phase 2: LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) source ↗
  6. Trial start Phase 1/Phase 2: LYT-300 in Healthy Volunteers source ↗
  7. Trial start Phase 1: PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects source ↗
  8. Trial start Phase 1/Phase 2: LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors source ↗
  9. Trial start Phase 2: LYT-100 in Post-acute COVID-19 Respiratory Disease source ↗
  10. Trial start Phase 2: LYT-100 in Patients With BCRL source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 2

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Director, Preclinical Research and DevelopmentBoston, MAOct 19, 2026Oct 20, 2026Not stated
PureTech does not accept agency resumes unless submitted through the portal on our ATS from a recruiting partner under contract for a particular assignment. PureTech will not be responsible for fees for resumes sent to employees or careers pages.PureTech HealthJan 22, 2020Oct 9, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT07284602Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Phase 3RecruitingJun 26, 20262029-11 (estimated)
NCT06717100Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and NintedanibPhase 1CompletedDec 17, 2024Feb 17, 2025 (actual)
NCT04652518LYT-100 in Post-acute COVID-19 Respiratory DiseasePhase 2TerminatedDec 11, 2020Jun 28, 2022 (actual)
NCT05829226A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)1CompletedDec 12, 2022Dec 31, 2025 (actual)
NCT07456800PK of Deupirfenidone Versus Pirfenidone in Older Healthy SubjectsPhase 1CompletedJul 12, 2021Jan 1, 2022 (actual)
NCT05321420LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Phase 2Active, not recruitingJul 22, 2022Oct 15, 2024 (actual)
NCT04666688LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid TumorsPhase 1/Phase 2CompletedDec 15, 2020Dec 12, 2024 (actual)
NCT04243837LYT-100 in Patients With BCRLPhase 2TerminatedMar 1, 2020Sep 9, 2022 (actual)
NCT05129865LYT-300 in Healthy VolunteersPhase 1/Phase 2CompletedDec 7, 2021Oct 18, 2023 (actual)

Connect

See your connections at PureTech Health on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback